Ixico Regulatory News (IXI)

IXICO plc

Appointment of Chief Financial Officer

17 September 2014, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that Susan Lowther FCMA has been appointed to the board as Chief Financial Officer with effect from 1 October 2014.

Susan (aged 54) was previously Group Chief Financial Officer and a director of Novacyt SA, a European company listed on the French Alternext exchange. Novacyt specialises in cancer and infectious disease diagnostic products and services, operating from four sites in France and the UK.

Prior to this she was Chief Financial Officer and a director of Lab21 Group Limited, which was acquired by Novacyt in June 2014 by way of a share for share transaction valuing the enlarged group at c.€40 million. Susan was previously Chief Executive Officer at BioWisdom Limited and has held finance roles in life science companies including RiboTargets, Lonza Biologics, Celltech Group and Monsanto.

Commenting on the appointment Derek Hill, CEO of IXICO, said: "We are delighted that Susan is joining the IXICO team. She brings a depth of financial and business experience that will help us continue to grow the business internationally."

Information in respect of Susan required pursuant to Schedule 2(g) of the AIM Rules for Companies is set out below.

Full name:

Susan Day Lowther

Current directorships:

TriSys Business Software Limited

Novacyt S.A.

Lab21 Limited

Lab21 Healthcare Limited

Lab21 Inc

Microgen Limited

Mercia Diagnostics Limited

Biotec Laboratories Limited

Selah Technologies Limited

Previous directorships:

BioWisdom Limited

BioWisdom SRS Limited

OmniViz Inc

NPTech Services Limited (Wholly owned subsidiary of Lab21 Limited which was dissolved in July 2014 as part of a group reorganisation)

Myconostica Limited (Wholly owned subsidiary of Lab21 Limited which was dissolved in August 2014 as part of a group reorganisation)

Myconostica Trustee Company Limited (Wholly owned subsidiary of Myconostica Limited which was dissolved in April 2014 as part of a group reorganisation)

Lab21 Diagnostic Services Limited (subsidiary of Lab21 Limited which was dissolved in April 2014 as part of a group reorganisation)

Enquiries:

IXICO plc

Derek Hill, CEO

Charles Spicer, VP Corporate Development

+44 20 3763 7499

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel

Clare Terlouw

+44 20 7418 8900

Daniel Stewart & Company (Joint Broker)

Mark Treharne

David Hart

+44 207 776 6550

FTI Consulting Limited (Investor Relations)

Simon Conway

John Dineen

+44 20 3727 1000